ArticleCureus2025
Chasing the Drop: Miami Versus Dual Criteria for Intraoperative Parathyroid Hormone Monitoring in Primary Hyperparathyroidism.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim To compare the diagnostic performance of the Miami criterion and the Dual criterion for intraoperative parathyroid hormone (IOPTH) monitoring in patients undergoing parathyroidectomy for primary hyperparathyroidism, and to assess factors contributing to operative failure. Methodology A single-center retrospective observational study was conducted involving 23 consecutive patients who underwent parathyroidectomy with IOPTH monitoring between January 2023 and June 2025. The Miami criterion (≥50% parathyroid hormone (PTH) reduction from baseline at 10 minutes) and the Dual criterion (≥50% reduction with final PTH in the normal range) were applied. Operative success, defined as normocalcemia at three months, served as the gold standard. Diagnostic performance was assessed by sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. Results At three months, 19 of 23 patients (82.6%) achieved normocalcemia. The Miami criterion demonstrated higher sensitivity (89.5%) and accuracy (78.3%) compared with the Dual criterion (78.9% and 69.6%, respectively). Both criteria showed high PPV (85.0% vs. 83.3%). Four operative failures (17.4%) were attributed to parathyroid carcinoma with metastases, non-localizing or ectopic adenomas, and vitamin D deficiency. Conclusions Both Miami and Dual IOPTH criteria reliably predicted postoperative normocalcemia, with the Miami criterion demonstrating higher sensitivity and accuracy. Operative failures were related to disease complexity rather than biochemical criteria. Advanced localization strategies and metabolic optimization should be integrated into perioperative planning to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.